Goldman Sachs
RXRX icon

Goldman Sachs’s Recursion Pharmaceuticals RXRX Stock Holding History

Goldman Sachs’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.6M Buy
6,065,661
+3,864,219
+176% +$14.9M ﹤0.01% 2495
2025
Q4 		$9M Buy
2,201,442
+939,822
+74% +$4.65M ﹤0.01% 3195
2025
Q3 		$6.16M Buy
1,261,620
+130,402
+12% +$685K ﹤0.01% 3462
2025
Q2 		$5.72M Sell
1,131,218
-364,645
-24% -$1.79M ﹤0.01% 3288
2025
Q1 		$7.91M Sell
1,495,863
-569,345
-28% -$4.15M ﹤0.01% 2911
2024
Q4 		$14M Buy
2,065,208
+525,504
+34% +$3.53M ﹤0.01% 2468
2024
Q3 		$10.1M Buy
1,539,704
+469,154
+44% +$3.36M ﹤0.01% 2712
2024
Q2 		$8.03M Buy
1,070,550
+173,530
+19% +$1.51M ﹤0.01% 2719
2024
Q1 		$8.94M Sell
897,020
-294,785
-25% -$3.28M ﹤0.01% 2574
2023
Q4 		$11.8M Buy
1,191,805
+527,032
+79% +$3.76M ﹤0.01% 2380
2023
Q3 		$5.09M Buy
664,773
+87,328
+15% +$871K ﹤0.01% 2959
2023
Q2 		$4.31M Buy
577,445
+42,318
+8% +$296K ﹤0.01% 3230
2023
Q1 		$3.57M Sell
535,127
-47,875
-8% -$380K ﹤0.01% 3373
2022
Q4 		$4.49M Buy
583,002
+224,936
+63% +$2.21M ﹤0.01% 3269
2022
Q3 		$3.81M Buy
358,066
+161,999
+83% +$1.64M ﹤0.01% 3384
2022
Q2 		$1.6M Sell
196,067
-13,342
-6% -$89.3K ﹤0.01% 4237
2022
Q1 		$1.5M Buy
209,409
+85,823
+69% +$912K ﹤0.01% 4486
2021
Q4 		$2.12M Buy
123,586
+104,919
+562% +$1.97M ﹤0.01% 4196
2021
Q3 		$429K Buy
18,667
+7,654
+69% +$217K ﹤0.01% 5287
2021
Q2 		$402K Buy
+11,013
New +$326K ﹤0.01% 5343

Other funds holding RXRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Goldman Sachs's RXRX Position: Q1 2026 in Review

Goldman Sachs increased its Recursion Pharmaceuticals (RXRX) stake by 176% in Q1 2026, buying an estimated $14.9M and bringing the position to 6,065,661 shares worth $18.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2495.

Goldman Sachs first reported a position in RXRX in Q2 2021 and has held it in 20 quarters since. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • Goldman Sachs held 6,065,661 shares of Recursion Pharmaceuticals worth $18.6M as of Q1 2026.
  • Goldman Sachs bought 3,864,219 Recursion Pharmaceuticals shares in Q1 2026, an estimated $14.9M.
  • Recursion Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2495 holding.
  • Goldman Sachs first reported a position in Recursion Pharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • 334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.